Ipratropium with salbutamol

How it works

Salbutamol stimulates beta-2 receptors to relax airway smooth muscle for rapid bronchodilation, while ipratropium blocks muscarinic receptors to reduce cholinergic bronchoconstriction, producing complementary effects.

Prescribing in practice

• When nebulised, shield the eyes from the mist because the ipratropium component can trigger acute angle-closure glaucoma if it contacts the eyes.
• Use cautiously in cardiovascular disease and arrhythmia given salbutamol's cardiac effects, and in prostatic or bladder outflow obstruction given the antimuscarinic component.
• Salbutamol can lower serum potassium, so caution is needed with concurrent hypokalaemia, particularly during acute severe attacks.

Monitoring

Monitor respiratory response, heart rate, tremor and, in acute or high-dose use, serum potassium, while watching for any visual symptoms during nebulisation.

Counselling the patient

• Keep the nebulised mist away from your eyes and report eye pain or blurred vision.
• Mild tremor or a faster heartbeat can occur and usually settles; seek help if symptoms persist or worsen.

Evidence & guidelines

Combining a short-acting antimuscarinic with a short-acting beta-2 agonist is well established in UK practice for COPD and acute airflow obstruction.